March 2020 – Cremona, Italy: Avantea partner in the new research project INTERSLA

INnovation, new TEchnological models and networks to treat ALS: INTERSLA, an ambitious project that aims - thanks also to Big Data analysis - to identify new therapeutic targets in the treatment of this rare disease: it has an incidence of new cases per year of 2-3 per 100 thousand, and it is extremely disabling.

The ultimate goal is to prevent irreversible neuromuscular damage: ALS determines a progressive loss of the motor function of the voluntary muscles that allow us to move but also to speak, swallow and breathe.

There are several innovative features that have made INTERSLA one of the 33 projects of excellence winners of the Lombardy Region call “Call Hub Research and Innovation”, partly financed with POR-FESR 2014-2021 funds.

Avantea will contribute swine animal models for ALS, in order to enable a more in-depth study on the onset and early diagnosis of the disease and to test potential new drug candidates.

You can find more information about INTERSLA here.